These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Icosapent ethyl: a review of its use in severe hypertriglyceridemia. Kim ES, McCormack PL. Am J Cardiovasc Drugs; 2014 Dec; 14(6):471-8. PubMed ID: 25428605 [Abstract] [Full Text] [Related]
10. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Am J Cardiol; 2011 Sep 01; 108(5):682-90. PubMed ID: 21683321 [Abstract] [Full Text] [Related]
11. A new pure ω-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Jacobson TA. Expert Rev Cardiovasc Ther; 2012 Jun 01; 10(6):687-95. PubMed ID: 22894624 [Abstract] [Full Text] [Related]
12. Effects of switching from omega-3-acid ethyl esters to icosapent ethyl in a statin-treated patient with elevated triglycerides. Kedia AW, Lynch E. Postgrad Med; 2015 Jun 01; 127(8):869-73. PubMed ID: 26453247 [Abstract] [Full Text] [Related]
13. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study). Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. J Clin Lipidol; 2012 Jun 01; 6(6):565-72. PubMed ID: 23312052 [Abstract] [Full Text] [Related]